CPRX Stock Summary and Trading Ideas (Catalyst Pharmaceuticals | NASDAQ:CPRX)

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.

Catalyst Pharmaceuticals trades on the NASDAQ stock market under the symbol CPRX.

As of January 17, 2025, CPRX stock price climbed to $22.78 with 3,571,513 million shares trading.

CPRX has a market cap of $2.72 billion. This is considered a Mid Cap stock.

Last quarter Catalyst Pharmaceuticals reported $129 million in Revenue and $.57 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.27.

In the last 3 years, CPRX traded as high as $24.27 and as low as $5.24.

The top ETF exchange traded funds that CPRX belongs to (by Net Assets): IJR, VTI, IWM, CALF, FBT.

CPRX has outperformed the market in the last year with a price return of +56.2% while the SPY ETF gained +28.0%. CPRX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +7.7% and +6.9%, respectively, while the SPY returned +3.0% and +1.0%, respectively.

CPRX support price is $22.05 and resistance is $23.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CPRX shares will trade within this expected range on the day.